This could be accomplished by leveraging synthetic lethality interactions specific to PKP1-overexpressing cancer cells or by developing approaches that selectively degrade the oncogenic cytoplasmic/nuclear pools of PKP1 without disrupting its tumor-suppressive membrane-associated functions. This evidence concerns the gene PKP1 and cancer.